RAD21
RAD21 (Double-strand-break repair protein rad21 homolog) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Lung cancer and 2 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
As a member of the cohesin complex, involved in sister chromatid cohesion from the time of DNA replication in S phase to their segregation in mitosis, a function that is essential for proper chromosome segregation, post-replicative DNA repair, and the prevention of inappropriate recombination between repetitive regions. The cohesin complex may also play a role in spindle pole assembly during mitosis. In interphase, cohesins may function in the control of gene expression by binding to numerous sites within the genome. May control RUNX1 gene expression. Binds to and represses APOB gene promoter. May play a role in embryonic gut development, possibly through the regulation of enteric neuron development. Location: Nucleus; Nucleus matrix; Chromosome; Chromosome, centromere (UniProt). Locus 8q24.11 (HGNC).
- Leukaemia: Open Targets association 0.65 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.64 with myeloproliferative neoplasm (MONDO_0020076)
- Lung cancer: Open Targets association 0.54 with lung cancer (MONDO_0008903)
- Acute myeloid leukaemia: Open Targets association 0.60 with acute myeloid leukaemia (MONDO_0018874); IntOGen driver in 2 cohorts (AML)
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUSC)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"RAD21" OR ABSTRACT:"RAD21" OR TITLE:"RAD21 cohesin complex component" OR ABSTRACT:"RAD21 cohesin complex component" OR TITLE:"Double-strand-break repair protein rad21 homolog" OR ABSTRACT:"Double-strand-break repair protein rad21 homolog" OR TITLE:"KIAA0078" OR ABSTRACT:"KIAA0078" OR TITLE:"hHR21" OR ABSTRACT:"hHR21" OR TITLE:"SCC1" OR ABSTRACT:"SCC1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RAD21, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rad21.json. Licence CC BY-NC 4.0.